US FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda announced that the FDA approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.